Nuvation Bio Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation

Reuters

Nov 04

<a href="https://laohu8.com/S/NUVB">Nuvation Bio</a> Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation

Nuvation Bio Inc. has provided an update highlighting recent developments across its oncology portfolio. The company reported that IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, received approval in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer (NSCLC), with 204 new patient starts in Q3 2025. Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering a pivotal study for high-grade IDH1-mutant glioma, with plans to potentially include high-risk, low-grade patients. NUV-1511, a clinical-stage drug-drug conjugate, is in Phase 1/2 evaluation, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company reported a cash balance of $549 million as of September 30, 2025, with additional funding available under a term loan agreement. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580226320"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580226320\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580226320?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 05:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580226320","market":"nz","top_or_hot":-1,"title":"Nuvation Bio Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> Inc. has provided an update highlighting recent developments across its oncology portfolio. The company reported that IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, received approval in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer (NSCLC), with 204 new patient starts in Q3 2025. Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering a pivotal study for high-grade IDH1-mutant glioma, with plans to potentially include high-risk, low-grade patients. NUV-1511, a clinical-stage drug-drug conjugate, is in Phase 1/2 evaluation, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company reported a cash balance of $549 million as of September 30, 2025, with additional funding available under a term loan agreement. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvation Bio Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvation Bio Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 05:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> Inc. has provided an update highlighting recent developments across its oncology portfolio. The company reported that IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, received approval in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer (NSCLC), with 204 new patient starts in Q3 2025. Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering a pivotal study for high-grade IDH1-mutant glioma, with plans to potentially include high-risk, low-grade patients. NUV-1511, a clinical-stage drug-drug conjugate, is in Phase 1/2 evaluation, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company reported a cash balance of $549 million as of September 30, 2025, with additional funding available under a term loan agreement. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVB","symbol_name":"Nuvation Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL790fV4:1","article_id":"2580226320","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580226320","pubTimestamp":1762206270,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nuvation Bio Inc. has provided an update highlighting recent developments across its oncology portfolio. The company reported that IBTROZI , a next-generation ROS1 inhibitor, received approval in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer , with 204 new patient starts in Q3 2025. Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering a pivotal study for high-grade IDH1-mutant glioma, with plans to potentially include high-risk, low-grade patients. NUV-1511, a clinical-stage drug-drug conjugate, is in Phase 1/2 evaluation, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company reported a cash balance of $549 million as of September 30, 2025, with additional funding available under a term loan agreement. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVB":"Nuvation Bio, Inc.","BK4007":"制药"},"translate_title":"Nuvation Bio在公司演示中强调了突破性的肿瘤学进展和IBTROZI的推出","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":0.9},"content_text":"Nuvation Bio Highlights Breakthrough Oncology Advances and IBTROZI Launch in Corporate Presentation\n    \n\nNuvation Bio Inc. has provided an update highlighting recent developments across its oncology portfolio. The company reported that IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, received approval in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer (NSCLC), with 204 new patient starts in Q3 2025. Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering a pivotal study for high-grade IDH1-mutant glioma, with plans to potentially include high-risk, low-grade patients. NUV-1511, a clinical-stage drug-drug conjugate, is in Phase 1/2 evaluation, while NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 and Phase 1b studies. The company reported a cash balance of $549 million as of September 30, 2025, with additional funding available under a term loan agreement. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}